Experience with BioTrace Medical’s Tempo Temporary Pacing Lead in Mitral Valve Surgeries Presented at Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting
Case series demonstrates the advantages of transvenous active-fixation Tempo Lead over epicardial leads for minimally invasive cardiac surgery procedures
MENLO PARK, Calif. -- BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27.
The series titled “A Case Series of the BioTrace Medical Tempo Active Fixation Lead in Cardiac Surgery—A Novel Technique for Post-Surgical Pacemaking,” describes a collection of re-operative robotic mitral valve surgeries performed at Thomas Jefferson University Hospital in Philadelphia, Pa. in which the Tempo Lead was successfully utilized for temporary perioperative transvenous pacing. The cases demonstrate the ability of the Tempo Lead to provide reliable temporary pacing when epicardial lead placement is challenging.
The Tempo Lead’s unique design – featuring novel retractable stabilizers and a soft tip – mitigates the risks of dislodgment and perforation, ensures stability during rapid pacing and facilitates patient ambulation in recovery.
“Detection and treatment of cardiac perforation or tamponade caused by epicardial leads is particularly problematic because these events, while rare, usually happen during lead removal outside of the operating room and in a setting with limited hemodynamic monitoring,” said Jordan Goldhammer, M.D., Cardiothoracic Anesthesiologist and Director of Cardiovascular Peri-Procedural Clinical Operations at Sidney Kimmel Medical College at Thomas Jefferson University. “In my experience so far, the transvenous Tempo Lead is simple and safe to remove and has allowed our patients to safely ambulate and get to physical therapy sooner before discharge.”
With U.S. FDA clearance and CE certification, the Tempo Lead is the only active-fixation temporary transvenous pacing lead available in the world. The Tempo Lead has been used in more than 10,000 U.S. procedures with a safety and performance profile superior to conventional temporary leads, as exemplified by a 0.04% cardiac perforation or tamponade rate1 compared to temporary epicardial lead bleeding complication rates ranging from .75% to 1%..
Related news
-
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world. Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such...
-
Diaphragm Pacemaker for Teen Featured on WSB-TV Atlanta
Fourteen year-old Sedarius was recently featured on WSB-TV Atlanta as the first pediatric patient to receive surgery to implant a diaphragm pacemaker in the state of Georgia. Sedarius was diagnosed with CCHS when he was eight years old, and required a tracheotomy and ventilator to breathe while he slept. The Avery Breathing Pacemaker will allow him to breathe without the need for a trach or ventilator and help improve his quality of life. He was able to return home within a few days, and it is expected that he...
-
Christie Medical Holdings, Inc. Partners with DO-PA A.S. for Turkey Distribution
As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the USA, VeinViewer®Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of VeinViewer® as a standard of care and are excited to partner with DO-PA Inc. as our authorized distributor for Turkey.DO-PA...
-
Outlook on the Medical Ceramics Global Market to 2026 - Identify Key Drivers and Challenges
According to Fast. MR research the report titled Global Medical Ceramics Market provides comprehensive information regarding influential factors. Data included in the report has been curated by our team of industry experts, considering relevant information about the market. This report discusses the growth and trends of various regions and segments of the market. Information such as market drivers, restraints, opportunities, trends, gross revenue, average product/service price, and market share of major players...
-
BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson`s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of DA01 in patients with PD. “It’s both exciting and humbling to be a part of...
Customer comments
No comments were found for Experience with BioTrace Medical’s Tempo Temporary Pacing Lead in Mitral Valve Surgeries Presented at Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting. Be the first to comment!